| Laura Christine Cappelli, MD | |
|
5501 Hopkins Bayview Cir, Suite 1b1, Baltimore, MD 21224-6821 | |
| (410) 550-8089 | |
| Not Available |
| Full Name | Laura Christine Cappelli |
|---|---|
| Gender | Female |
| Speciality | Internal Medicine |
| Experience | 14 Years |
| Location | 5501 Hopkins Bayview Cir, Baltimore, Maryland |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1225273840 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RR0500X | Internal Medicine - Rheumatology | D0078987 (Maryland) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Johns Hopkins Bayview Medical Center | Baltimore, MD | Hospital |
| Johns Hopkins Hospital, The | Baltimore, MD | Hospital |
| Sibley Memorial Hospital | Washington, DC | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Johns Hopkins University | 8921903147 | 2692 |
News Archive
Advanced Cell Technology, Inc., a leader in the field of regenerative medicine, today announced treatment of the final patient in the first patient cohort in its Phase 1/2 clinical trial for Stargardt's macular dystrophy (SMD) using retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs).
A new study published in Open Access journal PLOS Biology by the Global Biological Standards Institute (GBSI) and two leading economists estimates that, in the U.S. alone, approximately $28 billion per year is spent on preclinical research that is not reproducible.
InNexus Biotechnology Inc., a biopharmaceutical company creating and developing innovative solutions for cancer, inflammation and other difficult-to-treat diseases, announced today that it has filed for patent protection covering a novel antibody product for Age-related Macular Degeneration (AMD) and other eye disorders.
Human gut bacteria that feast on the yeast contained in fermented foods like bread and beer provides clues to new treatments for people suffering from bowel diseases.
› Verified 3 days ago
| Entity Name | Johns Hopkins University |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1922008549 PECOS PAC ID: 8921903147 Enrollment ID: O20031215000719 |
News Archive
Advanced Cell Technology, Inc., a leader in the field of regenerative medicine, today announced treatment of the final patient in the first patient cohort in its Phase 1/2 clinical trial for Stargardt's macular dystrophy (SMD) using retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs).
A new study published in Open Access journal PLOS Biology by the Global Biological Standards Institute (GBSI) and two leading economists estimates that, in the U.S. alone, approximately $28 billion per year is spent on preclinical research that is not reproducible.
InNexus Biotechnology Inc., a biopharmaceutical company creating and developing innovative solutions for cancer, inflammation and other difficult-to-treat diseases, announced today that it has filed for patent protection covering a novel antibody product for Age-related Macular Degeneration (AMD) and other eye disorders.
Human gut bacteria that feast on the yeast contained in fermented foods like bread and beer provides clues to new treatments for people suffering from bowel diseases.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Laura Christine Cappelli, MD 5501 Hopkins Bayview Cir, Suite 1b1, Baltimore, MD 21224-6821 Ph: (410) 550-8089 | Laura Christine Cappelli, MD 5501 Hopkins Bayview Cir, Suite 1b1, Baltimore, MD 21224-6821 Ph: (410) 550-8089 |
News Archive
Advanced Cell Technology, Inc., a leader in the field of regenerative medicine, today announced treatment of the final patient in the first patient cohort in its Phase 1/2 clinical trial for Stargardt's macular dystrophy (SMD) using retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs).
A new study published in Open Access journal PLOS Biology by the Global Biological Standards Institute (GBSI) and two leading economists estimates that, in the U.S. alone, approximately $28 billion per year is spent on preclinical research that is not reproducible.
InNexus Biotechnology Inc., a biopharmaceutical company creating and developing innovative solutions for cancer, inflammation and other difficult-to-treat diseases, announced today that it has filed for patent protection covering a novel antibody product for Age-related Macular Degeneration (AMD) and other eye disorders.
Human gut bacteria that feast on the yeast contained in fermented foods like bread and beer provides clues to new treatments for people suffering from bowel diseases.
› Verified 3 days ago
Dr. Leonard Anang Sowah, M.D. Rheumatology Medicare: Medicare Enrolled Practice Location: 22 S Greene St, Baltimore, MD 21201 Phone: 410-706-4619 Fax: 410-706-2062 | |
Dr. Bhavandeep Singh Bajaj, M.D. Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 3345 Wilkens Avenue, Suite L10, Baltimore, MD 21229 Phone: 410-644-4444 Fax: 410-644-4484 | |
Dr. Yonas Sisay, M.D. Rheumatology Medicare: Not Enrolled in Medicare Practice Location: 822 Guilford Ave, #100, Baltimore, MD 21202 Phone: 410-385-9672 | |
Dr. Stephen John Witanowski, MD Rheumatology Medicare: Medicare Enrolled Practice Location: 2700 Quarry Lake Dr, Suite 280, Baltimore, MD 21209 Phone: 410-469-5544 Fax: 410-585-2867 | |
Dr. Susrutha Kotwal, MD Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 4940 Eastern Ave, Mfl Bldg, West Tower, 6th Floor, Baltimore, MD 21224 Phone: 410-550-5018 | |
Dr. Mitesh G Trambadia, M.D. Rheumatology Medicare: Medicare Enrolled Practice Location: 6701 N Charles St Ste 5218, Baltimore, MD 21204 Phone: 443-849-3786 | |
Ronak K Patel, M.D. Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 201 E University Pkwy, Baltimore, MD 21218 Phone: 410-554-2000 |